Short Interest in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Declines By 46.6%

Posted by Donna Armstrong on Mar 29th, 2026

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 5,007 shares, a decline of 46.6% from the February 26th total of 9,382 shares. Based on an average trading volume of 23,217 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are short sold.

Institutional Trading of ALPS Medical Breakthroughs ETF

A number of institutional investors have recently made changes to their positions in the stock. Delta Investment Management LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF in the fourth quarter worth $6,112,000. LPL Financial LLC boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 438.7% during the fourth quarter. LPL Financial LLC now owns 42,755 shares of the company’s stock worth $2,190,000 after purchasing an additional 34,819 shares during the period. Jones Financial Companies Lllp bought a new stake in shares of ALPS Medical Breakthroughs ETF in the first quarter worth about $782,000. Stifel Financial Corp purchased a new position in ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $1,018,000. Finally, Virtu Financial LLC purchased a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter worth approximately $650,000.

ALPS Medical Breakthroughs ETF Stock Performance

Shares of SBIO stock opened at $48.36 on Friday. The business has a 50-day moving average of $50.90 and a 200 day moving average of $47.35. ALPS Medical Breakthroughs ETF has a 1-year low of $22.33 and a 1-year high of $54.79.

About ALPS Medical Breakthroughs ETF

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.